Dual MMP-9/12 Inhibition with AZD1236 Confers Neurovascular Protection and Reduces Post-Stroke Pain in Experimental Stroke Models.
Background: Stroke remains a leading cause of death and disability worldwide. Matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-12, contribute to early blood-brain barrier (BBB) disruption, neuroinflammation, haemorrhagic transformation, and intracerebral haemorrhage (ICH). Intravenous thrombolysis is the only widely used pharmacological therapy for acute ischaemic stroke, but its…
Dual inhibition of MMP-9 and MMP-12 with the drug AZD1236 offers significant neurovascular protection and alleviates post-stroke pain, according to experimental stroke models. This finding holds promise for the development of an adjunctive neuroprotective strategy to complement acute pharmacological treatment for ischaemic and haemorrhagic stroke, which currently has limited efficacy due to strict eligibility criteria and haemorrhagic risk associated with intravenous thrombolysis.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
